Bone marrow failure in children

Current Opinion in Pediatrics

Volumn 8, Issue 1, 1996, Pages 33-41

  Vlachos, Adrianna ^a   Lipton, Jeffrey M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APLASTIC ANEMIA; BLACKFAN DIAMOND ANEMIA; BONE MARROW DEPRESSION; BONE MARROW TRANSPLANTATION; CHILDHOOD DISEASE; DISEASE CLASSIFICATION; DYSKERATOSIS CONGENITA; ERYTHROBLASTOPENIA; FANCONI ANEMIA; GENE THERAPY; HEMATOPOIESIS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMOGENESIS; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STEM CELL;

ANEMIA, APLASTIC; BONE MARROW TRANSPLANTATION; CHILD; CYCLOPHOSPHAMIDE; ECTODERMAL DYSPLASIA; FANCONI ANEMIA; GRAFT VS HOST DISEASE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 0029921724     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199602000-00008     Document Type: Review

References (47)

1. Young NS, Alter BP: Aplastic Anemia Acquired and Inherited. Philadelphia: WB Saunders; 1994.
2. Bacigalupo A, for the Working Party on Severe Aplastic Anemia of the European Group of Bone Marrow Transplantation: Guidelines for the treatment of severe aplastic anemia. Haematologica 1994, 79:438-444. The European Group of BMT provides a valuable diagnostic algorithm for severe aplastic anemia and presents the various therapeutic options, including BMT, immunomodulation, and use of growth factors. They conclude that treatment should be individualized according to the patient's age, BMT donor status, and neutrophil count at presentation.
3. Storb R: Preparative regimens for patients with leukemias and severe aplastic anemia (overview): biological basis, experimental animal studies and clinical trials at the Fred Hutchinson Cancer Research Center. Bone Marrow Transplant 1994, 14(suppl 4):51-53.
4. Horstmann M, Stockschläder M, Kabisch H, Zander A: Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia transplanted with bone marrow from HLA-identical related donors [letter]. Blood 1995, 85:1404-1405.
5. Deeg HJ, Anasetti C, Petersdorf E, Storb R, Doney K, Hansen JA, Sanders J, Sullivan KM, Appelbaum FR: Cyclophosphamide plus ATG conditioning is insufficient for sustained hematopoletic reconstitution in patients with severe aplastic anemia transplanted with marrow from HLA-A, B, DRB matched unrelated donors [letter]. Blood 1994, 83:3417-3418.
6. Rosenfeld SJ, Kimball J, Vining D, Young NS: Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia. Blood 1995, 85:3058-3065.
7. Bacigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Locatelli F, Mori PG, Saracco P, Todeschini G, et al.: Antilymphocyte globulin, cyclosporin, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study of the EBMT SAA working party. Blood 1995, 85:1348-1353. This pilot study tests the addition of G-CSF to the proven ATG and cyclosporine A regimen for the medical management of acquired SAA. The very favorable early results support this new regimen as an excellent alternative for patients without an HLA-identical sibling BMT donor.
8. Hord JD, Gay JC, Whitlock JA, Janco RL, Edwards JR, Greer JP, Lukens JN: Long-term granulocyte-macrophage colony-stimulating factor and immunosuppression in the treatment of acquired severe aplastic anemia. J Pediatr Hematol Oncol 1995, 17:140-144. Medical treatment of children with SAA treated with ATG, prednisone, cyclosporine, and GM-CSF is beneficial. This regimen results in a decrease in initial morbidity, which the authors postulate is due to the decrease in associated infections secondary to an early increase in the neutrophil count.
9. Young NS, Barrett AJ: The treatment of severe acquired aplastic anemia. Blood 1995, 85:3367-3377. This comprehensive review summarizes a large and confusing body of data regarding the pathophysiology of SAA. The authors carefully analyze BMT and immunomodulation for the treatment of SAA. The role of hematopoietic growth factors is also considered.
10. Liu JM, Buchwald M, Walsh CE, Young NS: Fanconi anemia and novel strategies for therapy. Blood 1994, 84:3995-4007. In this excellent article, the authors give a complete summary of the FA phenotype, diagnosis of FA, genetic analysis with identification of the FA genes, function of the FACC gene, and treatment modalities including growth factors, BMT, and gene therapy.
11. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD: Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994, 84:1650-1655. This analysis of data from 388 patients with FA enrolled in the International FA Registry reveals the initial hematologic abnormalities encountered and the prevalence of myelodysplasia or leukemia (or both).
12. Miglierina R, Le Coniat M, Gendron M, Berger R: Diagnosis of Fanconi's anemia by flow cytometry. Nouv Rev Fr Hematol 1990, 32:391-399.
13. Arkin S, Brodtman D, Alter BP, Lipton JM: A screening test for Fanconi anemia using flow cytometry [abstract]. Blood 1993, 82(suppl 1 ):176.
14. Seyschab H, Friedl R, Sun Y, Schindler D, Hoehn H, Hentze S, Schroeder-Kurth T: Comparative evaluation of diepoxybutane sensitivity and cell cycle blockage in the diagnosis of Fanconi anemia. Blood 1995, 85:2233-2237. This report describes the results of a double-blind study that enrolled 66 patients with suspected FA for diagnosis, using diepoxybutane sensitivity and cell cycle disturbance flow analysis. The results were concordant in 63 patients; the three patients with discordant results all had overt leukemia.
15. Kohli-Kumar M, Morris C, DeLaat C, Sambrano J, Masterson M, Mueller R, Shahidi NT, Yanik G, Desantes K, Friedman DJ, et al.: Bone marrow transplantation in Fanconi anemia using matched sibling donors. Blood 1994, 84:2050-2054. Encouraging results of FA patients undergoing matched sibling BMT using low-dose cyclophosphamide, thoracoabdominal irradiation, and antithymocyte globulin are summarized. A low incidence of GVHD using ATG, cyclosporine, and prednisone is also noted.
16. Strathdee CA, Gavish H, Shannon WR, Buchwald M: Cloning of cDNAs for Fanconi's anemia by functional complementation. Nature 1992, 356:763-767.
17. Whitney MA, Jakobs P, Kaback M, Moses RE, Grompe M: The Ashkenazi Jewish Fanconi anemia mutation: Incidence among patients and carrier frequency in the at-risk population. Hum Mutat 1994, 3:339-341.
18. Segal GA, Magenis RE, Brown M, Keeble W, Smith TD, Heinrich MC, Bagby GC: Repression of Fanconi anemia gene (FACC) expression inhibits growth of hematopoietic progenitor cells. J Clin Invest 1994, 94:846-852. Using in vitro cell cultures, the authors studied the function of the FACC gene product in normal hematopoietic progenitor cells.
19. Youssoufian H: Localization of Fanconi anemia C protein to the cytoplasm of mammalian cells. Proc Natl Acad Sci U S A 1994, 91:7976-7979.
20. Youssoufian H, Auerbach AD, Verlander PC, Steimle V, Mach B: Identification of cytosolic proteins that bind to the Fanconi anemia complementation group C polypeptide in vitro. J Biol Chem 1995, 270:9876-9882. The authors demonstrate the binding of FACC to cytosolic proteins in FA and non-FA mammalian cells. This study represents an important step in understanding this enigmatic protein.
21. Walsh CE, Nienhuis AW, Samulski RJ, Brown MG, Miller JL, Young NS, Liu JM: Phenotypic correction of Fanconi anemia in human hematopoietic cells with a recombinant adeno-associated virus vector. J Clin Invest 1994, 94:1440-1448. Using a recombinant adenoassociated virus vector containing the FACC gene, the authors demonstrate the first case of recombinant adenoassociated virus gene correction in human hematopoietic progenitor cells. Efficient transduction and expression, leading to phenotypic correction of the defect, have profound implications for gene therapy in FA.
22. Drachtman RA, After BP: Dyskeratosis congenita. Dermatol Clin 1995, 13:33-39. The authors' extensive literature survey summarizes the clinical manifestations, evaluation, and treatment of patients with dyskeratosis congenita.
23. Oehler L, Reiter E, Friedl J, Kabrna E, Haas OA, Rosenkranz A, Lechner K, Geissler K: Effective stimulation of neutropoiesis with rhG-CSF in dyskeratosis congenita: a case report. Ann Hematol 1994, 69:325-327.
24. Dokal I, Luzzatto L: Dyskeratosis congenita is a chromosomal instability disorder. Leuk Lymphoma 1994, 15:1-7.
25. Lipton JM, Alter BP: Diamond-Blackfan anemia. In Clinical Disorders and Experimental Models of Erythropoietic Failure. Edited by Feig SA, Freedman MH. Boca Raton: CRC Press, 1993:39-67.
26. Vlachos A, Alter B, Buchanan G, Freedman M, Glader B, Lipton JM: The Diamond Blackfan Anemia Registry (DBAR): preliminary data [abstract]. Blood 1993, 82(suppl 1):88.
27. Bastion Y, Bordigoni P, Debré M, Girault D, Leblanc T, Tchernia G, Ball S, McGuckin C, Gordon-Smith EC, Békassy A, et al.: Sustained response after recombinant interleukin-3 in Diamond Blackfan anemia [letter]. Blood 1994, 83:617-618.
28. Olivieri NF, Feig SA, Valentino L, Berriman AM, Shore R, Freedman MN: Failure of recombinant human interleukin-3 therapy to induce erythropoiesis in patients with refractory Diamond-Blackfan anemia. Blood 1994, 83:2444-2450.
29. Mugishima H, Gale RP, Rowlings PA, Horowitz MM, Marmont AM, McCann SR, Sobocinski KA, Bortin MM: Bone marrow transplantation for Diamond-Blackfan anemia. Bone Marrow Transplant 1995, 15:55-58. The results of 10 patients with BDA undergoing BMT are reviewed. The 2-year probability of survival is 58% for these patients, but 72% for those who underwent transplantation using HLA-identical sibling donors.
30. Tsai PH, Arkin S, Lipton JM: An intrinsic progenitor defect in Diamond-Blackfan anemia. Br J Haematol 1989, 73: 112-120.
31. Perdahl EB, Naprstek BL, Wallace WC, Lipton JM: Erythrold failure in Diamond-Blackfan anemia is characterized by apoptosis. Blood 1994, 83:645-650.
32. Heegaard ED, Hornsleth A: Parvovirus: the expanding spectrum of disease. Acta Paediatr 1995, 84:109-117.
33. Miller R, Berman B: Transient erythroblastopenia of childhood in infants < 6 months of age. Am J Pediatr Hematol Oncol 1994, 16:246-248.
34. Cherrick I, Karayalcin G, Lanzkowsky P: Transient erythroblastopenia of childhood. Am J Pediatr Hematol Oncol 1994, 16:320-324. This prospective study of 50 patients with TEC reveals that 28% are in the recovery phase with reticulocytosis at presentation and 64% have an associated mild to moderate neutropenia.
35. Bonilla MA, Dale D, Zeidler C, Last L, Reiter A, Ruggeiro M, Davis M, Koci B, Hammond W, Gillio A, Weite K: Long-term safety of treatment with recombinant human granulocyte colony-stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994, 88:723-730. This article reports on the results of 54 patients with severe congenital neutropenias who were placed on G-CSF phase I and II studies. Patients with Kostmann syndrome showed a 91% response rate, whereas those with cyclic neutropenia had a 100% response rate. Important long-term effects such as osteopenia, myelodysplasia, and leukemia were noted in the patients with Kostmann syndrome only.
36. Imashuku S, Hibi S, Kataoka-Morimoto Y, Yoshihara T, Ikushima S, Morioka Y, Todo S: Myelodysplasia and acute myelold leukaemia in cases of aplastic anaemia and congenital neutropenia following G-CSF administration. Br J Haematol 1995, 89:188-190.
37. Weinblatt ME, Scimeca P, James-Henry A, Sahdev I, Kochen J: Transformation of congenital neutropenia into monosomy 7 and acute nonlymphocytlc leukemia in a child treated with granulocyte colony-stimulating factor. J Pediatr 1995, 126:263-265.
38. Bishop NJ, Williams DM, Compston JC, Stirling DM, Prentice A: Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. Br J Haematol 1995, 89:927-928.
39. Dong F, Hoefsloot LH, Schelen AM, Broeders LCAM, Meijer Y, Veerman AJP, Touw IP, Löwenberg B: Identification of a nonsense mutation in the granulocyte-colony-stimulating factor receptor in severe congenital neutropenia. Proc Natl Acad Sci U S A 1994, 91:4480-4484.
40. Guba SC, Sartor CA, Hutchinson R, Boxer LA, Emerson SG: Granulocyte colony-stimulating factor (G-CSF) production and G-CSF receptor structure in patients with congenital neutropenia. Blood 1994, 83:1486-1492.
41. Sandoval C, Parganas E, Wang W, Ihle JN: Lack of alterations in the cytoplasmic domains of the granulocyte colony-stimulating factor receptors in eight cases of severe congenital neutropenia [letter]. Blood 1995, 85:852-853.
42. Wright DG, Kenney RF, Oette DH, LaRussa VF, Boxer LA, Malech HL: Contrasting effects of recombinant human granulocyte-macrophage colony-stimulating factor (CSF) and granulocyte CSF treatment on the cycling of blood elements in childhood-onset cyclic neutropenia. Blood 1994, 84:1257-1267. The use of GM-CSF and G-CSF are compared in this crossover study of three patients with cyclic neutropenia. GM-CSF diminishes the oscillations associated with this disorder while modestly elevating the neutrophil count. G-CSF, however, greatly influences the neutrophil count and amplifies the oscillations of all circulating blood elements. The authors therefore postulate the abnormality in this disorder to be in the more primitive progenitor.
43. Schmitz S, Franke H, Wichmann HE, Diehl V: The effect of continuous G-CSF application in human cyclic neutropenia: a model analysis. Br J Haematol 1995, 90:41-47. This article defines the defect in cyclic neutropenia by comparing clinical data with a previously postulated computer-simulation model of this disorder. The differential response to the cytokines, G-CSF, and GM-CSF, provides a basis for understanding the feedback regulation of neutrophil production.
44. Weinblatt M, Petrikovsky B, Bialer M, Kochen J, Harper R: Prenatal evaluation and in utero platelet transfusion for thrombocytopenia absent radii syndrome. Prenat Diagn 1994, 14:892-896.
45. Symonds RP, Clark BJ, George WD, Bryant PE, Liu N, Connor JM: Thrombocytopenia with absent radii (TAR) syndrome: a new increased cellular radiosensitivity syndrome. Clin Oncol R Coll Radiol 1995, 7:56-58.
46. Hedberg VA, Lipton JM: Thrombocytopenia with absent radii: a review of 100 cases. Am J Pediatr Hematol Oncol 1988, 10:51-64.
47. Alter BP, Young NS: The bone marrow failure syndromes. In Hematology of infancy and childhood, edn 4. Edited by Nathan DG, Oski FA. Philadelphia: WB Saunders; 1993:216-316.